Nifedipine in the Treatment of Migraine in Patients with Raynaud's Phenomenon

Publisher Website
Google Scholar
Abstract
To the Editor: We1 2 3 and others4 , 5 have shown that the slow calcium-channel-blocking agent nifedipine is effective in the treatment of Raynaud's phenomenon. It has been suggested that in some patients vasospasm may be "ubiquitous."6 , 7 The efficacy of nifedipine in the treatment of coronary vasospasm8 , 9 and of Raynaud's phenomenon prompted a study of its role in the treatment of migraine in patients with associated idiopathic Raynaud's phenomenon. The efficacy of nifedipine was assessed in a prospective double-blind randomized, cross-over trial in eight patients (six women and two men; mean age, 55.4; mean duration of migraine, 18.75 years; mean duration of Raynaud's . . .